Monopar Therapeutics Inc.

NASDAQ•MNPR

CEO: Dr. Christopher M. Starr Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2019-12-19

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.

Contact Information

1000 Skokie Boulevard, Suite 350, Wilmette, IL, 60091, United States

847-388-0349

www.monopartx.com

Market Cap

$411.18M

P/E (TTM)

-22.5

17.5

Dividend Yield

52W High

$105.00

52W Low

$26.06

52W Range

45%

Rank61Top 91.5%

2.0

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.48+336.36%

4-Quarter Trend

FCF

-$2.09M+94.74%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Cash Position Surges Post-Financing Cash and equivalents reached $127.7M by September 30, 2025. Strong financing provided runway estimated through December 31, 2027.

Major Capital Raise Completed September 2025 capital raise provided $91.9M net cash inflow. Financing activities generated $92.0M cash flow for the nine months.

R&D Spending Increased Sharply Nine-month R&D expenses rose $2.88M to $5.96M. Driven by ALXN1840 manufacturing and increased R&D personnel costs.

ALXN1840 NDA Preparation ALXN1840 NDA submission planned for early 2026. Long-term data sustained neurological and hepatic improvements versus SoC.

Risk Factors

Continued Operating Losses Expected Expect continued substantial operating losses for the foreseeable future. Profitability remains uncertain without successful commercial product sales realization.

Future Funding Dependency High Future operations depend on raising sufficient capital on acceptable terms. Current funds estimated to last through December 31, 2027.

Rising Operating Expenses Pressure Total operating expenses increased $5.46M for nine months. R&D and G&A costs rose due to advancing pipeline programs.

Regulatory Approval Uncertainty ALXN1840 regulatory approval process remains lengthy, expensive, and uncertain. Unable to guarantee successful New Drug Application outcome.

Outlook

Finalize ALXN1840 NDA Filing Assemble regulatory package for ALXN1840 to file NDA submission targeted for early 2026. Advance radiopharmaceutical pipeline development concurrently.

Advance Radiopharmaceutical Trials Advance MNPR-101-Zr imaging trial and MNPR-101-Lu therapeutic trial. Continue late preclinical development for MNPR-101-Ac.

Expand Drug Development Pipeline Identify and license novel targets complementing current radiopharmaceutical and rare disease programs. Expand pipeline through internal research efforts.

Leverage Team Experience Strategically Utilize senior team expertise in acquisitions, development, and commercialization to establish leading biopharmaceutical company presence.

Peer Comparison

Revenue (TTM)

AKBA

$236.19M

+47.5%

RGNX

$170.44M

+104.5%

CTMX

$113.63M

-10.3%

Gross Margin (Latest Quarter)

BCYC

100.0%

+1705.8pp

GOSS

100.0%

+0.0pp

LXRX

94.2%

+4.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
MLTX	$1.20B	-4.7	-67.1%	17.8%
CTMX	$1.14B	39.8	44.5%	0.0%
SVRA	$1.06B	-9.8	-84.0%	11.8%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 19, 2026

EPS:-$0.45

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data